Journal
LEUKEMIA
Volume 27, Issue 6, Pages 1391-1393Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/leu.2013.34
Keywords
monoclonal gammopathy of undetermined significance; MGUS; acute leukemias; myelodysplastic syndromes; population-based screening
Categories
Funding
- National Cancer Institute, National Institutes of Health, Bethesda, MD [CA107476, CA168762, CA100707, CA 83724]
- Jabbs Foundation, Birmingham, United Kingdom
- Henry J. Predolin Foundation, USA
Ask authors/readers for more resources
The purpose of this study was to determine if there is an increased risk of acute leukemia and myelodysplastic syndromes (MDS) in persons with monoclonal gammopathy of undetermined significance (MGUS). We used a large population-based cohort of individuals systematically screened for the presence or absence of MGUS. MGUS status was then linked to the diagnosis of acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL) and MDS. A total of 17 315 patients age 50 and older (605 MGUS and 16 710 controls) with a cumulative 435 021 person-years of follow-up were studied. MGUS patients had a significantly higher risk of developing MDS compared with controls, hazard ratio 2.4 (95% CI 1.08, 5.32), P = 0.031. There was no statistically significant increase in the risk of AML (RR 1.36 P = 0.675), and no increased risk of developing ALL.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available